Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex Pharmaceuticals ( NASDAQ:VRTX ) First Quarter 2024 Results Key Financial Results Revenue: US$2.69b (up 13% from...
Vertex stock advanced Tuesday as analysts debated the company's pain drug with one saying it could eventually generate $11.4 billion in sales.